VALN · Valneva SE
$6.75
-0.21 (-3.02%)
At close · Aug 24
Market Cap
$659.97M
Shares
94.82M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.75
Open$6.68
Day$6.60–6.80
52W close$4.78–12.20
Avg vol 30d134K
Short int159K · 0.2% float · 7.8d
Short vol37%
Last earningsAug 13, 2026
DataMay 2021–Aug 2026
Up next
Next earnings call
Nov 13, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15.9 · calm
Equity put/call 0.68
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−10%
below
Price vs 50-day avg
+24%
above
RSI (14)
70
neutral
MACD trend
Positive
52-week position
27%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+36%
trailing
6-month return
−34%
trailing
YTD return
−23%
this year
Relative strength
−46%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $7 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.17% of float · ▼ -4.1% MoM · 7.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
20 holders — near 3-yr high, broad support
Squeeze score
58
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
71%
annualized · 1-yr
Max drawdown
−61%
past year
ATR
4.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Dec 31, 2023
Contributions towards Phase IV costs
·
30%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−10%
Bearish
Price vs 50-day avg
+24%
Bullish
RSI (14)
70
Neutral
MACD trend
Positive
Bullish
52-week position
27%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $5 › 200d $7 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.17% of float · ▼ -4.1% MoM · 7.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
20 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $5
Now $7 · 27%
Range high $12
vs 200-day avg -10%
vs 50-day avg +24%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VALN
this stock
Valneva SE
|
$659.97M | -23.5% | — | — | 0.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.91B | +20.8% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.30B | +7.3% | +20.8% | 20.5 | 3.3% |
|
ARGX
Argenx SE
|
$64.66B | +20.2% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$57.97B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VALN | -4.4% | +36.1% | -34.2% | +35.8% | -23.5% |
| SPY | -1.2% | +3.3% | +12.2% | +2.2% | +12.0% |
| vs SPY | -3.2% | +32.8% | -46.4% | +33.6% | -35.4% |
Key facts
CIK
1836564
CUSIP
92025Y103
13F (30d)
16 filings
16 filers
Visit website
Investor relations